A new magnetic resonance imaging contrast agent being tested by researchers not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing types.
A new magnetic resonance imaging contrast agent being tested by researchers not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing types.